DDInter1042 DDInter666
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
Eribulin {u} (Compound) treats {v} (Disease) breast cancer
Eribulin {u} (Compound) binds {v} (Gene) TUBB
Eribulin {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Eribulin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Verapamil
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paliperidone
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Eribulin {u} may lead to a major life threatening interaction when taken with {v} Escitalopram
Eribulin (Compound) treats breast cancer (Disease)
Eribulin (Compound) binds TUBB (Gene)
Eribulin (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Eribulin may cause a minor interaction that can limit clinical effects when taken with Verapamil
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin may lead to a major life threatening interaction when taken with Teriflunomide
Eribulin may lead to a major life threatening interaction when taken with Escitalopram